Daré Bioscience, Inc.
DARE
$2.88
-$0.04-1.37%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 139.94% | -252.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 139.94% | -252.52% | |||
| Cost of Revenue | -83.85% | 56,790.00% | |||
| Gross Profit | 84.10% | -85,646.11% | |||
| SG&A Expenses | 15.69% | -2.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.49% | 12.74% | |||
| Operating Income | 14.98% | -15.10% | |||
| Income Before Tax | 20.49% | -17.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.49% | -17.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.49% | -17.10% | |||
| EBIT | 14.98% | -15.10% | |||
| EBITDA | 17.82% | -15.20% | |||
| EPS Basic | 27.19% | -24.61% | |||
| Normalized Basic EPS | 34.36% | -38.18% | |||
| EPS Diluted | 27.51% | -25.15% | |||
| Normalized Diluted EPS | 34.36% | -38.18% | |||
| Average Basic Shares Outstanding | 9.23% | -6.04% | |||
| Average Diluted Shares Outstanding | 9.23% | -6.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||